OSIS shares plunged 15.36% to close at $239.59 from the previous close of $282.87 in the most recent completed trading session. Primary catalyst: Post-earnings sell-off despite beating Q3 estimates, driven by concerns over timing headwinds, unchanged full-year guidance, and management warnings on Mexico contracts, DHS shutdown, Middle East conflicts, and supply chain issues.

ADTN shares plunged 17.25% in the latest session, closing at $15.18 after the prior close of $18.34. Primary catalyst: Market reaction to Q1 2026 earnings released after market close on May 4, with non-GAAP EPS of $0.14 beating estimates of $0.09, but GAAP loss of $0.01 per share and ongoing cost pressures.

BellRing Brands ( BRBR ) shares plunged 43.09% to $9.88 in the most recent trading session. The primary catalyst was a disappointing Q2 fiscal 2026 earnings report, with adjusted EPS of $0.14 missing estimates of $0.31 by 55% and revenue of $598.7 million falling short of $608.8 million expectations.

Shopify (SHOP) shares plunged 10.25% to close at $114.48 from the previous close of $127.55. Primary catalyst: Disappointing Q2 revenue guidance overshadowed a Q1 earnings beat with 34% revenue growth to $3.17 billion and strong gross merchandise volume (GMV) of $100.7 billion.

PLTR shares declined 5.89% to $137.43 during today's trading session, following a close of $146.03 on the prior session. Primary catalyst: Investor disappointment over a slight miss in U.

GeneDx Holdings ( WGS ) shares plunged 48.54% to close at $34.95, following the previous close of $67.93. Primary catalyst: Q1 2026 earnings miss with EPS of -$0.28 versus expected -$0.06, and revenue of $102.3 million missing consensus of $112.5 million.

IPGP shares plunged 26.51% to $89.89 in early trading on May 5, 2026, following Q1 earnings release before the market open. Q1 revenue beat estimates at $265.5 million, up 17% year-over-year, driven by industrial solutions demand.

Aptiv PLC ( APTV ) shares plunged 11.36% to 52.77 during Monday's session. The sell-off followed Q1 2026 earnings that beat estimates with adjusted EPS of $1.71 versus $1.58 expected and revenue of $5.1 billion up 5% year-over-year.

PYPL shares plunged 10.65% to $45.02 in early trading on May 5, 2026, from the previous close of $50.39. Primary catalyst: Q1 2026 earnings beat estimates with non-GAAP EPS of $1.34 (vs.

Novo Nordisk is scheduled to report Q1 2026 results on May 6, 2026, before market open. Analysts expect EPS of $0.87, down about 5% year-over-year from Q1 2025's $0.92.

Analysts expect Q2 fiscal 2026 EPS of $1.50, up 3.4% from $1.45 in the year-ago quarter. Revenue consensus stands at $24.83 billion, reflecting 5.1% year-over-year growth.

Analysts expect Q4 FY2026 revenue of $1.47 billion, aligning with company guidance midpoint and implying 18% year-over-year growth. Consensus non-GAAP EPS forecast stands at $0.58, matching Arm Holdings' guidance and up from $0.55 in the prior-year quarter.

Analysts expect Q1 2026 EPS of C$1.93, a 47% increase from C$1.31 in Q1 2025. Consensus revenue forecast stands at C$13.91 billion, up from C$12.45 billion year-over-year.

Analysts expect Q1 2026 revenue of approximately $8.35 billion, up about 2% from $8.2 billion in Q1 2025. Consensus EPS estimate around $5.60, implying a slight decline from $5.96 in the year-ago quarter.

Analysts expect KKR to report Q1 2026 EPS of around $1.28, up 11% from $1.15 in Q1 2025. Revenue consensus stands at approximately $1.43 billion to $2.4 billion, reflecting robust year-over-year expansion.

Analysts expect Q1 2026 EPS of around $0.21, up from $0.17 in Q4 2025. Consensus revenue forecast stands at approximately $9.2 billion for the quarter.

Analysts expect Q1 2026 adjusted EPS of $1.80, up about 2% from $1.76 in Q1 2025. Revenue consensus stands at $8.49 billion, a 2.9% increase from $8.25 billion last year.

Anheuser-Busch InBev reported Q1 2026 revenue of $15.267 billion, up 5.8% organically from $13.628 billion in Q1 2025, beating consensus estimates around $14.7 billion. Underlying EPS rose 20.8% to $0.97 from $0.81 year-over-year, surpassing analyst expectations of approximately $0.90-$0.91.

Vertex reported Q1 2026 total revenue of $2.99 billion, up 8% year-over-year from $2.77 billion, driven by cystic fibrosis (CF) franchise strength. Non-GAAP diluted EPS (earnings per share) came in at $4.47, surpassing consensus estimates around $4.23-$4.43; GAAP EPS was $4.02.

Analysts expect Q1 2026 revenues of approximately $13.8 billion, up slightly from $13.7 billion in Q1 2025. Consensus adjusted EPS estimate is around $0.72-$0.74 per share, down about 20% year-over-year from $0.92 due to product mix shifts and cost pressures.